The transcriptional regulation of cardiomyocyte polyploidization and its relevance in cardiac regeneration

REACTIVA aims to promote heart regeneration by reactivating adult diploid cardiomyocytes through a newly identified regulatory network and inhibiting a specific transcription factor.

Subsidie
€ 2.500.000
2024

Projectdetails

Introduction

The mammalian heart is a non-regenerative organ due to the extremely limited ability of fully differentiated cardiomyocytes (CMs) to proliferate. While neonatal hearts still contain mostly diploid CMs and regenerate efficiently, physiological postnatal CM polyploidization/hypertrophy ensures the contractile capacity of the adult myocardium but represents a roadblock to cardiac regeneration.

Problem Statement

Due to this limitation, diseases that provoke CM loss, like acute ischemia, frequently lead to heart failure.

Project Overview

REACTIVA will establish a new strategy for heart regeneration based on the reactivation of a dormant endogenous mechanism, thereby achieving unprecedented advances in the field of cardiac regenerative biology.

Research Findings

In mice, the proportion of adult diploid CMs (ADCs) correlates with regenerative ability. However, efforts to identify a molecular signature for ADCs have been unsuccessful, which has precluded exploring their roles in heart regeneration.

Using an improved methodology for single-CM RNAseq, my group has identified a molecular signature of ADCs related to the fetal program and controlled by a single repressor transcription factor. This factor is specifically expressed in the polyploid CM population (PCM) and its inhibition in the postnatal mouse heart robustly increases ADC abundance and proliferative activity.

Hypothesis

Based on these findings, we propose that ADCs underlie a vestigial endogenous mechanism for adult mammalian heart renewal and that their stimulation will promote heart regeneration.

Objectives

REACTIVA will exploit our new findings on ADCs to:

  1. Fully characterize the ADC regulatory network, identifying factors to modulate it.
  2. Identify and trace ADCs in the adult heart, defining their niches and contribution to renew and expand the CM population during heart homeostasis, aging, and disease.
  3. Use the generated knowledge to induce ADC activation with the goal of promoting adult mammalian heart regeneration.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.500.000
Totale projectbegroting€ 2.500.000

Tijdlijn

Startdatum1-10-2024
Einddatum30-9-2029
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.)penvoerder

Land(en)

Spain

Vergelijkbare projecten binnen European Research Council

ERC Starting...

Harnessing Novel Micropeptides in Cardiomyocytes to promote Cardiac Regeneration

Novel.CaRe aims to enhance cardiac regeneration post-myocardial infarction by using micropeptides to stimulate cardiomyocyte proliferation and maturation through innovative gene therapy approaches.

€ 1.592.281
ERC Advanced...

Programming the EPIcardium to CURE broken hearts

EPICURE aims to decode human epicardial development and regeneration using pluripotent stem cell-derived epicardioids, enhancing insights for cardiac repair through advanced imaging and CRISPR techniques.

€ 2.499.999
ERC Consolid...

Mechanisms and consequences of cell state transitions during heart regeneration

This project aims to uncover the coordinated cellular responses in zebrafish heart regeneration post-injury using single-cell genomics and computational methods to enhance understanding of organ repair mechanisms.

€ 2.000.000
ERC Proof of...

Universal Cardiac Mesoangioblasts for treating DMD Dilated Cardiomyopathy

The project aims to develop immune-privileged cardiac mesoangioblasts that can be converted to cardioblasts for targeted treatment of dilated cardiomyopathy, enhancing heart repair.

€ 150.000
ERC Advanced...

Restoring anisotropy in living tissues 'in situ'

This project aims to enhance cardiac tissue regeneration by restoring structural anisotropy using ultrasound, improving therapy outcomes through a multidisciplinary and technology-driven approach.

€ 3.056.887

Vergelijkbare projecten uit andere regelingen

EIC Pathfinder

Cardiogenomics meets Artificial Intelligence: a step forward in arrhythmogenic cardiomyopathy diagnosis and treatment

The project aims to integrate genomics, proteomics, and structural analyses to clarify genotype-phenotype relationships in arrhythmogenic cardiomyopathy, paving the way for novel therapies.

€ 3.740.868
EIC Pathfinder

Comprehensive Analysis of RBM20-induced Dilated Cardiomyopathies using Omics Approaches and Repair Interventions

CARDIOREPAIR aims to identify and therapeutically target RBM20 mutations in dilated cardiomyopathy using high-throughput genomics and bioengineering to improve heart health outcomes.

€ 4.349.410
EIC Pathfinder

Enabling advances in diagnosis, patient stratification and treatment for dilated cardiomyopathy patients and families.

The DCM-NEXT consortium aims to enhance genetic testing and develop novel therapies for dilated cardiomyopathy by leveraging extensive clinical and omics data from 11,750 patients.

€ 4.137.668
EIC Pathfinder

Engineering a living human Mini-heart and a swimming Bio-robot

The project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease.

€ 4.475.946